Salah-uddin Ahmed

Salah-uddin Ahmed serves as Professor and Associate Dean for Research and Graduate Education in the Department of Pharmaceutical Sciences at Washington State University College of Pharmacy. His expertise spans rheumatoid arthritis, osteoarthritis, and gout research with emphasis on epigenetic and posttranslational mechanisms driving inflammation.

His academic credentials include:

• PhD in nutrition and chemoprevention, Hamdard University, Department of Toxicology, New Delhi, India
• Master of Science in toxicology, Hamdard University, New Delhi, India
• Bachelor of Science in zoology and chemistry, Rajasthan University, Jaipur, India

Dr. Ahmed's research investigates cytokine networks (IL-6, IL-1β, TNF-α) in autoimmune diseases, focusing on epigenetic regulation, ubiquitin-proteasome pathways, and microRNA therapeutics. His lab develops targeted inhibitors for rheumatoid arthritis and gout, bridging molecular mechanisms with clinical applications through NIH-funded projects. Current work emphasizes TAK1 signaling and cannabinoid receptor modulation as novel therapeutic avenues.

Analysis of his 15 most recent publications reveals consistent focus on synovial fibroblast pathophysiology and inflammatory cascade interruption. Key trends include microRNA-based interventions (e.g., miR-17), natural compounds (EGCG, thymoquinone), and proteasomal degradation strategies targeting Mcl-1 and TRAF proteins. His work demonstrates strong translational potential with multiple in vivo arthritis models.

His scientific recognition includes:

• Graduate Faculty of the Year (2020)
• Medical Honoree from The Inland Northwest Arthritis Foundation (2019)
• ACR/REF-Abbott Health Professional Graduate Preceptorship Award (2012)

As principal investigator, Dr. Ahmed directs NIH R01-funded microRNA therapy research and mentors F31 predoctoral fellows like Ruby J. Siegel. His $2.5M+ grant portfolio includes Rheumatology Research Foundation projects on guanylate binding proteins in gout. He actively serves on NIH study sections and editorial boards for Arthritis Research & Therapy, shaping field standards through peer review.

His laboratory collaborates with University of Washington Rheumatology Division, integrating WSU's pharmaceutical sciences expertise with clinical rheumatology. The team employs multi-omics approaches to identify druggable targets in cytokine signaling, maintaining strong industry partnerships for therapeutic development.